-
公开(公告)号：WO2021183318A2
公开(公告)日：2021-09-16
申请号：PCT/US2021/020401
申请日：2021-03-02
发明人： MITRAGOTRI, Samir , WU, Debra
IPC分类号： G01N33/50 , A61K31/704 , A61K31/7068 , A61K47/69 , A61P35/00 , A61K9/1271 , G01N33/5011 , G01N33/5044
摘要： The technology described herein is directed to in vitro methods of identifying or selecting combinations of therapeutic agents that are effective in vivo. These methods provide improved methods of treatment, e.g., treatment of cancer. Further, provided herein are novel combinations of anti-cancer agents which are demonstrated to have surprising efficacy.
-
-
63.发明申请
公开(公告)号：WO2021180780A1
公开(公告)日：2021-09-16
申请号：PCT/EP2021/056036
申请日：2021-03-10
摘要： Treatment and/or diagnosis of a cancer type characterized by expressing zinc transporter ZIP4. The present invention is directed to nanocarriers functionalized with a ligand capable to bind to the extracellular domain of zinc transporter ZIP4, for use in the treatment and/or diagnosis of a cancer type characterized by expressing ZIP4.
-
64.发明申请
公开(公告)号：WO2021165227A1
公开(公告)日：2021-08-26
申请号：PCT/EP2021/053711
申请日：2021-02-16
IPC分类号： A61K9/107 , A61K39/00 , A61K39/39 , A61K47/69 , A61K49/18 , A61P29/00 , A61P37/02 , A61P37/06
摘要： The present invention provides nanoparticles comprising a) a micelle comprising an amphiphilic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less, and b) at least one peptide comprising at least one T cell epitope. The present invention further provides pharmaceutical compositions comprising these nanoparticles and the use of the compositions for suppressing specific immune responses.
-
65.发明申请
公开(公告)号：WO2021163466A1
公开(公告)日：2021-08-19
申请号：PCT/US2021/017838
申请日：2021-02-12
发明人： LIU, Yang , WANG, Yin , LIU, Yan , BAILEY, Christopher
摘要： The present invention relates to treating TP53-mutated AML using a Hypoxia-Inducible Factor (HIF inhibitor). The invention further relates to a new HIF inhibitor formulation with longer half-life and significantly improved therapeutic effect for TP53-mutated AML.
-
公开(公告)号：WO2021163242A1
公开(公告)日：2021-08-19
申请号：PCT/US2021/017535
申请日：2021-02-11
发明人： VEISEH, Omid , NASH, Amanda , BACHHAV, Bhagyashree, Kishor , ORIGEL MARMOLEJO, Carlos, Alberto , BERMAN, Damon , SCHREIB, Christian , SEGATORI, Laura , TRUBELJA, Alen , IGOSHIN, Oleg, A. , HECHT, Andrew, D.
摘要： The present disclosure provides expression constructs designed to provide for expression of therapeutic proteins from engineered cells. The engineered cells may be encapsulated into implantable elements that allow for the therapeutic protein to be released into from the capsule while protecting the cell from the immune system of a patient into which the capsule is implanted.
-
公开(公告)号：WO2021160667A1
公开(公告)日：2021-08-19
申请号：PCT/EP2021/053204
申请日：2021-02-10
申请人： NOVOCHIZOL SA
摘要： The present invention is directed to a new cross-linked chitosan, preparations, compositions and uses thereof. In particular, the invention relates to nanoparticles and compositions thereof useful as active agents and delivery systems for at least one bioactive agent.
-
公开(公告)号：WO2021153635A1
公开(公告)日：2021-08-05
申请号：PCT/JP2021/002917
申请日：2021-01-27
申请人： 株式会社ファルネックス
IPC分类号： A61K47/24 , A61K9/08 , A61K9/107 , A61K9/12 , A61K38/08 , A61K45/00 , A61K47/14 , A61K47/69 , A61P5/06 , A61P35/00 , A61P41/00 , C07C69/003 , C07D307/20 , C07D493/04
摘要： 本発明は、安全性の高い非ラメラ液晶形成性組成物を提供する。本発明は、下記一般式（Ｉ）で表される両親媒性化合物とリン脂質とを含む、リン脂質により生体適合性が向上した非ラメラ液晶形成性組成物であって、式中、Ｘ及びＹはそれぞれ水素原子を表すか又は一緒になって酸素原子を表し、ｎは１又は２を表し、ｍは１又は２を表し、Ｒは１つ以上の水酸基を有する親水性基を表す、組成物に関する。
-
公开(公告)号：WO2021142516A1
公开(公告)日：2021-07-22
申请号：PCT/AU2021/050027
申请日：2021-01-18
摘要： The present invention relates to compositions and methods facilitating the non-invasive administration (such as oral administration) of therapeutic proteins or peptides (such as insulin) which maintain biological activity when absorbed. The composition of the present invention comprises a therapeutic amount of a conjugate, wherein the conjugate comprises a quantum dot and a therapeutically effective peptide or protein.
-
公开(公告)号：WO2021129945A1
公开(公告)日：2021-07-01
申请号：PCT/EP2019/087110
申请日：2019-12-27
发明人： FRANK, Annika , HARTMANN, Jessica , BUCHHOLZ, Christian , RENGSTL, Benjamin , BILLMEIER, Arne Marten , SAHIN, Ugur , SCHMOLDT, Hans-Ulrich , HELLER, Philipp , LUI, Bonny Gaby , SCHLEGEL, Anne
IPC分类号： A61K38/17 , A61K47/69 , C07K14/47 , C07K14/705 , A61P35/00 , A61K38/1709 , A61K47/62 , A61K47/6455 , A61K47/6807 , A61K47/6811 , A61K47/6929 , A61K47/6931 , C07K14/70517 , C07K2319/01 , C07K2319/21 , C07K2319/33
摘要： The present disclosure generally relates to therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells may be generated in vitro/ex vivo as well as in vitro by delivering nucleic acid encoding an antigen receptor for genetic modification to cells using particles comprising the nucleic acid and a targeting molecule for targeting the immune effector cells, wherein the targeting molecule is a designed ankyrin repeat protein (DARPin). In particular, DARPins are described herein which are high-affinity binders for CDS binding to the CDS receptor on human and non-human primate (NHP) cells. Nanoparticles functionalized with CD8- targeting DARPins (CDS-DARPin) can deliver genes exclusively and specifically to human CD8+ T cells in vitro and in vivo.
-
-
-
-
-
-
-
-
-
搜索结果
985 条记录 (耗时 0.027 秒)
